Personalized treatment of women with early breast cancer: A risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online
Beate Jahn, Ursula Rochau, Christina Kurzthaler, Michael Hubalek, Rebecca Miksad, Gaby Sroczynski, Mike Paulden, Marvin Bundo, David Stenehjem, Diana Brixner, Murray Krahn, Uwe Siebert
Dive into the research topics of 'Personalized treatment of women with early breast cancer: A risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online'. Together they form a unique fingerprint.